TABLE 1.
IC50s for AD101 inhibition of NL4-3/env chimeric virus replication in primary CD4+ T cells
| env clone, chimera, or mutant | AD101 IC50 (nM)a | Relative fold differenceb |
|---|---|---|
| CC1/85 cl.7 | 0.004 | 1 |
| CC101.19 cl.7 | >20,000 | >5 × 106, > |
| CC1/85 cl. 7(8) | >20,000 | >5 × 106, > |
| CC101.19 cl.7(8) | 0.6 | 150, > |
| CC1/85 cl.7(H308P) | 2 | 500, > |
| CC1/85 cl. 7(K305R, H308P) | 400 | 100,000, > |
| CC1/85 cl.7(K305R, H308P, A316V, G321E) | >20,000 | >5 × 106, > |
| CC1/85 cl.7(K305R) | 0.0004 | 10, < |
| CC1/85 cl.7(A316V, G321E) | 0.0006 | 7, < |
| CC1/85 cl.7(K305R, A316V, G321E) | 0.000006 | 700, < |
| CC101.19 cl.7(R305K, P308H, V316A, E321G) | 0.02 | 5, > |
| CC101.19 cl.7(P308H) | 0.0002 | 20, < |
| CC101.19 cl.7(R305K, P308H) | 1 | 250, > |
a
Approximate IC50s for AD101 inhibition curves were calculated by fitting to a sigmoidal dose-response curve by nonlinear regression using the program Prism (GraphPad Software) for the average data sets shown in Fig. 4 and 5.
b
Relative fold difference in IC50 for AD101 compared to CC1/85 cl.7, which is used as a reference. > and < indicate that IC50 is respectively greater or less than that for CC1/85 cl.7.